INTRODUCTION
Although levels of prostate-specific antigen (PSA) in blood are strongly associated with risk and outcome of prostate cancer (PCa) [1] and PSA-based screening can reduce PCa mortality, current screening algorithms lead to overdetection and consequential overtreatment of PCa [2] . Hence, the search continues for novel biomarkers that could contribute to the diagnostic information above and beyond that provided by the widely used conventional testing for total PSA levels in the blood.
Nucleic acid-based gene expression signatures have been suggested to aid in the prediction of unfavourable PCa compared to the established clinical predictors [3] .
We studied the gene expression levels of 10 nucleic acid markers assessing their suitability for discriminating cancerous tissue of different pathological stage and grade from non-cancerous tissue.
Each of these markers has previously been suggested to contribute diagnostic or predictive value in PCa diagnostics. PCA3 (prostate cancer antigen 3), discovered in 1999 [4] , has recently been launched as a commercial application for the detection of increased mRNA expression in prostate cells shed into urine, and is claimed to improve the inadequacies of PSA-based diagnosing of PCa [5] . BMP6 (bone morphogenetic protein 6) [6] , FGF-8b (fibroblast growth factor 8, isoform b) [7] , KLK2 (kallikrein-related peptidase 2) [8] , KLK4 (kallikrein-related peptidase 4) [9] , KLK15
(kallikrein-related peptidase 15) [10] , PSCA (prostate stem cell antigen) [11] and Trpm8 (transient receptor potential protein 8) [12] have been reported to be overexpressed in PCa whereas the expression of KLK3 (kallikrein-related peptidase 3 encoding the PSA protein) [8] and MSMB (microseminoprotein-beta) has been reported to be decreased in cancerous prostate tissue [13] .
The study was performed by analyzing prostate tissue samples from 87 PCa patients with a truly quantitative, internally standardized real-time reverse transcription-PCR (RT-PCR) assay technique, described previously [14] . Based on traditional RT-PCR methods, data are often only qualitative or semi-quantitative, and reliable quantitative information is difficult, if not impossible, to achieve with gel-based techniques or by relative quantification using house-keeping genes. The unavoidable loss in recovery during the several steps of RT-PCR protocol such as RNA extraction and reverse transcription may also lead to underestimation of the original levels of mRNA. These problematic aspects were taken into account in our work, where closed-tube real-time detection of the PCR amplification product by time-resolved fluorometry was designed to increase the robustness and sensitivity of the assay. Additionally, an artificial internal standard was used to bypass the need to measure reference gene expression and to correct for the inherent variation in mRNA recovery. To our knowledge, this is the first study to truly and reliably quantify the mRNA levels of these target genes in a prostate tissue cohort.
MATERIALS AND METHODS

Patient cohort and sample collection
Tissue samples were obtained from 87 PCa patients immediately after radical prostatectomy. From each prostate, a tissue sample wedge was obtained from the suspected cancerous area and another from an assumed control area within minutes from the surgical removal of the prostate (Supplemental Figure 1) 
RNA extraction and cDNA synthesis
Tissue samples were collected and processed as described previously [15] . A known amount of internal RNA standard -RNA from an artificial, mutant form of KLK3 gene called mmPSA [16] was added to each sample after cell lysis.
Real-time PCR
Time-resolved fluorometry, including lanthanide chelate-labeled probes that specifically recognize amplified targets [14] , was utilized for the real-time detection of the PCR amplification. The oligonucleotides were purchased from Thermo Fisher Scientific (Germany) and MWG (Germany) (Supplemental Table 2 ). The lanthanide probes were designed, labelled and purified in-house [19, 20] . PCR conditions for each assay are described in Supplemental Table 3 . Samples were run in triplicate reactions and the thermocycling was performed as described previously [15] with HotMaster™ Taq DNA Polymerase (Eppendorf, Hamburg, Germany) or AmpliTaq® Gold DNA Polymerase (Applied Biosystems, Foster City, CA, USA) with the corresponding buffers. Specific purified PCR products were produced as described previously [15] and used as external standards in concentrations that are presented in Supplemental Table 4 .
Data analysis
The samples were considered positive only if all three PCR replicates were above the limit of detection (LOD, defined as the lowest standard which produces a rise in fluorescence signal) and positive (detectable expression), since many specimens had mRNA levels equal to the LOD of the assay.
RESULTS
Expression of the 10 gene targets
The frequencies of detectable expression of the 10 gene targets are shown in Of the 10 mRNA targets, only the expression levels of PCA3 and PSCA were significantly different (p<0.05) in cancerous than histologically benign tissue. The cancerous tissue samples had significantly higher levels of PCA3 mRNA (median 5.75-fold difference) than the histologically benign samples whereas PSCA mRNA levels were significantly lower in cancerous tissue (median 2.9-fold difference) ( Figure 1 , Table 2 ). Among the 46 patients that provided one cancerous and one benign sample with detectable PCA3 mRNA expression, the median PCA3 mRNA ratio between the cancerous and normal sample was 2.9 with an interquartile range of 0.68−15 and with 10th and 90th percentiles at 0.24 and 638, respectively. In 31/46 patients, the cancerous sample had higher PCA3 mRNA expression. There were also the same number of patients (n=46) providing one cancerous and one benign sample with detectable PSCA mRNA expression. Among that group, PSCA mRNA levels were lower in the cancerous sample for 25/46 patients and the median PSCA mRNA ratio between the histologically benign and cancerous sample was 1.1 with an interquartile range of 0.51-3.6 and with 10 th and 90 th percentiles at 0.07 and 9.8, respectively.
ROC curve analysis of PCA3 and PSCA mRNA expression in cancerous and histologically benign prostatic tissues produced AUC values of 0.673 for PCA3 and 0.414 for PSCA (Figure 2 ).
Association of gene expression with Gleason grade and pathologic stage
Of the 10 studied mRNA targets, only the expression of KLK3 mRNA was significantly associated with Gleason grade (p=0.018) with higher levels in cancerous tissue of grade ≤3 than in grade ≥4 (Table 3) . Advanced pathologic stage was significantly associated with higher levels of KLK15 mRNA (p=0.032) and PCA3 mRNA (p=0.015) ( Table 4) . None of the other eight mRNAs were significantly associated with the pathologic stage.
Effect of cancer cell percentage on the levels of gene expression
We also analysed samples containing either less or more than 50% cancerous tissue as separate groups, but the cancer cell percentage in the tissue specimens did not have a significant impact on the mRNA levels (Supplemental Table 5 ).
DISCUSSION
Despite continued controversy on PSA testing and a widely acknowledged need of novel markers predicting PCa risk or outcome, it does not appear likely that any novel marker will single-handedly prove to be more widely useful than PSA. In this study, we determined quantitatively the mRNA levels of suggested PCa marker genes in cancerous and non-cancerous tissue samples freshly obtained from prostatectomy specimens to nominate a subset of the markers in this panel that hold potential promise for distinguishing cancerous prostate tissue from non-cancerous tissue. Each of these genes has previously been described in the literature but our study is unique in reporting the level of gene expression as absolute mRNA copy numbers determined by quantitative, internally standardized real-time RT-PCR assays. By utilizing an artificial internal standard as has been recommended [23] but rarely used, our approach provides accurate data and bypasses the need and pitfalls of measuring any reference gene expression.
We found the median expression levels of the most abundantly expressed genes -MSMB, KLK3, KLK4 and KLK2 -to be up to 10 5 -fold higher than the mRNA transcript levels of the gene targets with the lowest expression levels but none of them were significantly differently expressed in cancerous versus non-cancerous tissue. Only the expression of two of the less abundant target mRNAs -PCA3 and PSCA -was significantly different in the cancerous tissue compared to the histologically benign tissue despite the considerable overlap in the expression of all 10 genes between cancerous and histologically benign tissue. PCA3 was the marker that provided the best discrimination between the groups. However, the magnitude of PCA3 overexpression in cancerous compared to the non-cancerous tissue was smaller in this cohort than in prior reports. In the first and original PCA3 study by Bussemakers et al a 10-100-fold overexpression was observed using
Northern blot [4] and later on Hessels et al found an 11-or 66-fold difference between cancerous and normal tissues from cancer-affected prostates depending on whether the cancerous samples contained less or more than 10% cancer cells [24] . However, we did not find any direct correlation between the cancer cell percentage and levels of PCA3 mRNA or any of the target mRNAs in this panel. The level of PCA3 overexpression has been reported to vary also in other studies [21, 25] and our observation of a 5.75-fold upregulation, detected by RT-PCR, is at the lower end of the range.
Recently Robert et al [25] described a 30-fold upregulation in cancerous tissue compared to normal areas of cancer-affected prostates, but they also noted that the level of PCA3 overexpression was further increased when cancerous tissue was compared to BPH tissue, and they suggested that upregulation of PCA3 expression may start early on in the disease progression before the cells turn truly cancerous. That can be described as a cancer field effect which causes molecular level alterations in histologically benign-appearing tissue. Other PCA3-related observations of field effect in prostate cancer have also been reported [26] and the cohort studied in our work could conceivably present similar field effect-related changes in mRNA expression. Magnitude of PSCA underexpression was moderate as well and underexpression in cancerous tissue is contrary to the earlier reports of PSCA overexpression in PCa [11] . A limitation of this study, considering the likelihood of a significant field effect, is the lack of control tissues from non-PCa patients such as those that were included in the recent study of Robert et al [25] . Such a study is in progress.
Gleason grade did not associate with the mRNA copy numbers apart from the modestly lower expression of KLK3 mRNA at a higher tumor grade. However, an advanced pathologic stage was associated with the overexpression of KLK15 and PCA3 mRNAs. This is supported by the association between KLK15 levels and Gleason grade in prostate tissue that was previously reported by Stephan et al [10] , and adds KLK15 to the group of most interesting markers of this panel but further studies are needed to find out the potential connection between these markers and prognosis.
In this cohort, the follow-up times were too short (<3 years) to justify any prognostic analyses.
CONCLUSIONS
Of the 10 target genes, PCA3 and PSCA mRNAs were significantly differently expressed in cancerous than in histologically benign tissue of cancerous prostates and KLK15 mRNA in more advanced cancer stage. However, the differences in PCA3 expression in particular were not as pronounced as previously has been reported, leading us to assume indications of field effect in the non-cancerous tissue of the cancerous prostates. To obtain a better view on the true roles of these 10 RNA markers in prostate carcinogenesis, we suggest further studies especially regarding the bestperforming markers identified in this study.
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